Moleculin completes follow-on

On Feb. 9, cancer company Moleculin Biotech Inc. (NASDAQ:MBRX) raised $5 million through the sale of 3.7 million units at $1.35 in a follow-on underwritten by Roth Capital Partners and National Secur...